ArticleInsights into imaging2025
Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Added diagnostic value of pseudocapsule and ADC heterogeneity beyond ccLS v2.0 in small renal masses.Abdominal radiology (New York) · 2026Article
- Combined radiological approach for characterization of solid renal masses: a proposed strategy for integrating the RENAL nephrometry score into the clear cell likelihood score.BMC medical imaging · 2026Article
- Reply to the Letter to the Editor: Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.Insights into imaging · 2026Article
- Letter to the Editor: Diagnostic performance of the clear cell likelihood score integrated with cystic degeneration or necrosis on MR imaging for identifying clear cell renal cell carcinoma in cT1 solid renal masses.Insights into imaging · 2026Article
- Multimodal deep learning model for multiclass classification of renal tumors.NPJ digital medicine · 2026Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
objectivesTo evaluate the diagnostic value of the clear cell likelihood score (ccLS) integrated with cystic degeneration or necrosis on renal MR imaging for diagnosing clear cell renal cell carcinoma (ccRCC) in cT1 solid renal masses (SRMs).
methodsThis retrospective study consecutively enrolled patients with pathologically confirmed SRMs who underwent MRI at the First Medical Center of the Chinese PLA General Hospital between January 2022 and February 2024. Three radiologists independently scored all cT1 SRMs using ccLS and ccLS integrated with cystic degeneration or necrosis (cn-ccLS), with discrepancies reconciled by consensus. Sensitivity, specificity, and accuracy were used to assess the performance of ccLS and cn-ccLS.
resultsA total of 287 patients with 293 masses were included in this study. The sample comprised 229 ccRCCs (78%), 64 other tumors. The sensitivity of cn-ccLS was significantly higher than ccLS (92% vs 74%; p < 0.001), with equal specificity to ccLS (88% vs 91%; p > 0.05). For cT1a and cT1b SRMs, the sensitivity of cn-ccLS was significantly higher than ccLS (cT1a: 90% vs 74%, p < 0.05; cT1b: 98% vs 75%, p < 0.001).
conclusionsIncorporating cystic degeneration or necrosis into the ccLS system significantly enhances the diagnostic performance of the ccLS system for ccRCC in cT1 SRMs. However, future validation of the ccLS system through large-sample, multi-center, and prospective studies is still required. CRITICAL RELEVANCE STATEMENT: Incorporating cystic degeneration or necrosis into the ccLS system enhances performance for ccRCC in cT1 SRMs. It may enhance the value of ccLS and assist radiologists in their daily diagnostic work. KEY POINTS: The cn-ccLS effectively reduced the proportion of ccRCC among ccLS 3 lesions. cn-ccLS better diagnosed ccRCC for cT1a or cT1b renal masses than ccLS. ccRCC sensitivity was improved, but the impact on non-ccRCC remains unevaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.